Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions
ABSTRACT
Objective
To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT).
Design
The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data.
Patients
The review focuses on MHT‐related outcomes in women with natural‐timed menopause captured within observational studies, RCTs, and pooled data from pivotal meta‐analyses and reviews.
Measurements
Available published data are scrutinized. Available evidence and notably lacking data from women not adequately represented in published MHT trials, such as those with socioeconomic adversity, significant comorbidities, and minority ethnic backgrounds, are highlighted and deliberated.
Results
The impact of MHT differs significantly between demographics. Current consensus recommendations for MHT emphasize the importance of tailoring type, route, dose, and duration of therapy to individual needs and risk/benefit ratio through shared decision‐making. MHT impact can change over time. Current MHT data support its benefits for treating menopause symptoms and a potential window of opportunity in midlife to benefit skeletal health. Limitations of current evidence highlight menopause health inequalities and underscores the need for further research.
Conclusions
This review recommends tailored use of MHT for well‐defined indications, recognizing its value for menopause symptom relief and skeletal benefits for many midlife women. MHT may be used as long as benefits outweigh risks, through shared decision‐making. There is insufficient clinical evidence to support the long‐term use of MHT in some contemporary cohorts of women accessing MHT in clinical practice.
